Tech Company Financing Transactions
NormOxys Funding Round
Care Capital and Index Ventures participated in a $17.5 million Series B funding round for NormOxys. This venture round was announced on 5/24/2010.
Transaction Overview
Company Name
Announced On
5/24/2010
Transaction Type
Venture Equity
Amount
$17,500,000
Round
Series B
Investors
Care Capital (Lead Investor) (Argeris Karabelas)
Index Ventures (Francesco De Rubertis)
Proceeds Purpose
Proceeds from the financing will enable NormOxys to advance its lead drug candidate, OXY111A, into clinical development in 2010 in two diseases, chronic heart failure and cancer, and complete clinical studies through proof-of-concept in both of these indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
300 Market St.
Boston, MA 02135
USA
Boston, MA 02135
USA
Phone
Website
Email Address
Overview
NormOxys is developing a novel class of small molecule drugs, oxyrens, which enhance the body's ability to deliver oxygen more efficiently to diseased tissues with oxygen deficiency.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Conrad Bletzer
Co-Founder
Jean-Marie Lehn
Co-Founder
Claude Nicolau
Vice President
John Hey
Browse more venture capital transactions:
Prev: 5/24/2010: NitroSecurity venture capital transaction
Next: 5/25/2010: Compass Labs venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs